Dyne Bio Inc. has developed a new bioactive compound from red algae, Gelidium elegans.
Dyne-NAO is obtained by decomposing agar which is a major component of red algae, Gelidium elegans.
that is one of Korea’s main marine resources. We produce neoagarotetraose(DP4) and neoagarohexaose(DP6)
through the enzymatic bio conversion process. As a new bioactive compound, we verified their effectiveness and safety.
Currently we are working on developing them as food and pharmaceutical materials.
Dyne-NAO was completed safety evaluations and has significant effects on improving metabolic syndrome
(obesity, diabetes and hyperlipidemia), immune modulation, moisturizing and anti-oxidant. Consequently,
we are promoting business with Dyne-NAO as a high value functional biomaterial.
Structure of Dyne-NAO
Category | Compound
DP4
DP6
CAS registry number
16033-31-1
25023-93-2
Molecular weight
630.547
C24H38O19
Molecular formula
C24H38O19
C36H56O28
Biological efficacy
Efficacy
Biological activity
Metabolic Syndrome
- Obesity
- Diabetes
- Hyperlipidemia
- Hepatic injury
• Obesity
- Reduction of the adipocytes size
- Upregulation of lipolysis related gene expression
- Downregulation of lipogenesis related gene expression
• Diabetes
- Improvement of insulin resistance
- Improvement of glycemic control
• Hyperlipidemia
- Improvement of serum lipid profiling
- Upregulation of lipid receptor related gene expression (SREBP2, PCSK9)
• Hepatic injury
- Activation of antioxidant genes via Nrf2 activation for acute liver damage
- Prevention and treatment of chronic liver injury via inhibition of the TFG-β/Smad pathway
Immune system
• Immune cell stimulation
- Macrophage, NK cells, T cells, etc.
• Dendritic cells maturation
- Activation of NK, Non NK immunocyte
- Identification of Toll-like Receptor (TLR)
• Inhibition of tumor growth (in vivo)
• Prevention & treatment of Microbial infection (in vivo)
• Preventing & improving sepsis (in vitro, in vivo)
• Improving & treating rheumatoid arthritis and atopic dermatitis
• Anti-viral effect against Norovirus
Patent
No
Patent
Registration No.
1
Agar-derived neoagarooligosaccharide complex for the prevention
and treatment of obesity and/or diabetes comprising enzyme
reaction products of beta agarase DagA and agar
Rep. of Korea 10-1632262
Japan JP6088657
China
ZL201380059074.6
2
Composition comprising neoagarooligosaccharide for preventing
or treating sepsis or septic shock
Rep. of Korea 10-1675359
China. ZL201580075360.0
U. S. 10,548,916
3
Composition for preventing, alleviating, or treating arthritis
or osteoporosis, containing neoagarooligosaccharide
Rep. of Korea 10-1923062
Japan JP 6815525
U. S. 10,933,086
4
Mutant strain of Streptomyces coelicolor, method for producing β-agarase using the same and method for manufacturing
neoagarooligosaccharide using the same
Rep. of Korea 10-1919962
Japan JP6923759
China ZL201980007385.5
U.S. 11,466,248
5
Manufacturing method of agar for raw material of neoagarooligosaccharide mixture and use thereof
Rep. of Korea 10-2214973
Articles
Anti-Obesity and Anti-Diabetic Effect of Neoagarooligosaccharides on High-Fat Diet-Induced Obesity in Mice. Marine drugs. 2017;15(4):90.
Neoagarooligosaccharides enhance the level and efficiency of LDL receptor and improve cholesterol homeostasis. Journal of Functional Foods. 2017;38:529-539.
Neoagarohexaose-mediated activation of dendritic cells via Toll-like receptor 4 leads to stimulation of natural killer cells and enhancement of antitumor immunity. BMB Reports. 2017;50(5):263-268.
Neoagarooligosaccharides prevent septic shock by modulating A20- and cyclooxygenase-2–mediated interleukin-10 secretion in a septic-shock mouse model. BBRC. 486(4), 998-1004, 2017.
Toxicological evaluation of neoagarooligosaccharides prepared by enzymatic hydrolysis of agar. Regulatory Toxicology and Pharmacology. 2017;90:9-21.
In vitro and in vivo Investigation for Biological Activities of Neoagarooligosaccharides Prepared by Hydrolyzing Agar with β-Agarase. Biotechnology and Bioprocess Engineering. 2017;22:489-496.
Safety evaluation of β-agarase preparations from Streptomyces coelicolor A3(2). Regulatory Toxicology and Pharmacology. 2019; 101, 142-155.
Non-targeted metabolomics unravels a media-dependent prodiginines production pathway in Streptomyces coelicolor A3(2). PLoS ONE. 2018;13(11): e0207541.
Implications of agar and agarase in industrial applications of sustainable marine biomass. Applied Microbiology and Biotechnology 2020;104:2815–2832.
Hepatoprotective effect of neoagarooligosaccharide via activation of Nrf2 and enhanced antioxidant efficacy. Biol Pharm Bull. 2020;43(4), 619-628.
Antiviral efficacy of orally delivered neoagarohexaose, a nonconventional TLR4 agonist, against norovirus infection in mice. Biomaterials 2020;263, 120391.
Neoagarooligosaccharide Protects Against Hepatic Fibrosis via inhibition of TGF‐β/Smad Signaling Pathway. Int. J. Mol. Sci. 2021;22. 2041.
